PMID: 9429222Jan 16, 1998Paper

S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma

Melanoma Research
R KärnellB Kågedal

Abstract

Elevated levels of the phaeomelanin metabolite 5-S-cysteinyldopa and the eumelanin metabolite 6-hydroxy-5-methoxyindole-2-carboxylic acid in urine and serum have been shown in previous studies to correlate with disseminated malignant melanoma. Immunohistochemical detection of S100B protein is an acknowledged method for the diagnosis of malignant melanoma, and it has been suggested that rising serum levels of S100B protein are associated with the survival rate of patients with malignant melanoma. In the present study serum levels of S100B protein and urinary concentrations of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid were measured in 91 patients with histopathologically verified malignant melanoma. At the time of sampling 13 patients were in clinical stage I, 13 in stage II and 65 in stage III. The urinary levels of the melanin metabolites were determined by automated high performance liquid chromatography, and the serum levels of S100B protein by an immunoradiometric assay with two monoclonal antibodies. The overall survival rate was most strongly associated with the serum levels of S100B protein (P < 0.001), but there was also a significant correlation to urinary levels of 5-S-cysteinyldopa (P < 0.001)....Continue Reading

Citations

Jun 1, 1997·Medical Oncology·J Hansson
Oct 12, 2012·Amino Acids·Nadine TandlerJens Pietzsch
Aug 27, 1998·Cancer Letters·M R Ros-BullónJ H Martínez-Liarte
Sep 30, 1999·Cancer Letters·M R Ros-BullónJ H Martínez-Liarte
Jan 31, 2002·Journal of Chromatography. B, Biomedical Sciences and Applications·J Hartleb, R Arndt
Aug 22, 2000·The British Journal of Dermatology·L Brochez, J M Naeyaert
Dec 22, 2012·Future Medicinal Chemistry·Kira G HartmanDavid J Weber
Sep 17, 2004·Scandinavian Journal of Clinical and Laboratory Investigation·K ArstrandB Kågedal
Jan 22, 2002·International Journal of Cancer. Journal International Du Cancer·Johanna NikkolaSeppo Pyrhönen
Oct 4, 2011·Mayo Clinic Proceedings·Shanique R PalmerSvetomir N Markovic
Oct 1, 2014·Biochemistry·Michael C CavalierDavid J Weber
Mar 10, 2006·Pigment Cell Research·Kazumasa WakamatsuShosuke Ito
Jul 19, 2016·Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)·H MatsunakaF Furukawa
Feb 5, 2014·Journal of Proteome Research·Charlotte WelinderGyörgy Marko-Varga
Jul 24, 2002·Journal of Cutaneous Pathology·Ning LiJag Bhawan
Jun 24, 2003·Rapid Communications in Mass Spectrometry : RCM·E RagazziP Traldi
Jul 26, 2002·Melanoma Research·K StoitchkovT Le Bricon
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E D MårtensonJ Hansson
May 1, 2010·Oncology Letters·Mays Al-ShaerChris Papageorgio
Sep 14, 2000·Melanoma Research·R KärnellU Ringborg
Sep 26, 2001·Archives of Pathology & Laboratory Medicine·A SlominskiM C Mihm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.